Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
AFT Leaves X Over AI-Generated Images of Minors 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
BETHESDA, Md., April 05, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) (“IGC”) announces today that it has sold its ten percent holding in Brilliant Hallmark for a consideration of four million shares of IGC.
As a result of this transaction, 4,000,000 IGC common shares previously issued to Brilliant Hallmark, on August 4, 2016, will be returned and retired, thereby reducing the outstanding IGC shares from approximately 28,272,667 million before the sale to approximately 24,272,667 million after the sale. In addition, the Brilliant Hallmark investment will be removed from the IGC balance sheet with an associated reduction of approximately $1.88 million. The Company does not expect to record a gain or loss from this transaction.
“This strategic move is consistent with our Board’s mandate to consolidate our corporate focus on developing cannabis-based therapies while efficiently disposing with all non-core assets. In the past twelve months, the Company has retired almost seven million common shares, and exited from non-core assets in China, Hong Kong, and Malaysia while closing overseas subsidiaries and offices. We remain committed to streamlining operations and this transaction represents another significant step in executing on our initiatives,” states Ram Mukunda, CEO of IGC.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see risk factors discussed in India Globalization Capital, Inc.’s Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
